N@N

Derma Sciences Announces Fourth Quarter 2010 Financial Results Conference Call

^{Published on 2011-03-23 07:51:48 - Market Wire}
 

PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on March 30, 2011 to discuss the financial results for the fourth quarter ended December 31, 2010. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

The conference call is scheduled to begin at 11:00 a.m. ET (Eastern Time). The results will be released before the opening of the market that same day.

To access the conference call, U.S.-based listeners should dial (888) 563-6275 and international listeners should dial (706) 634-7417. All listeners should provide the following passcode: 54576672.

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Companya™s website, [ www.dermasciences.com ]. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.

Following the end of the conference call, a replay will be available through April 6, 2011, and can be accessed by dialing (800) 642-1687 within the U.S. or (706) 645-9291 outside of the U.S. All listeners should provide the following passcode: 54576672. The webcast will also be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.

For more information please visit [ www.dermasciences.com ].